These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 12384447

  • 1. A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia.
    Spiekermann K, Bagrintseva K, Schoch C, Haferlach T, Hiddemann W, Schnittger S.
    Blood; 2002 Nov 01; 100(9):3423-5. PubMed ID: 12384447
    [Abstract] [Full Text] [Related]

  • 2. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
    Spiekermann K, Dirschinger RJ, Schwab R, Bagrintseva K, Faber F, Buske C, Schnittger S, Kelly LM, Gilliland DG, Hiddemann W.
    Blood; 2003 Feb 15; 101(4):1494-504. PubMed ID: 12406902
    [Abstract] [Full Text] [Related]

  • 3. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.
    Grundler R, Thiede C, Miething C, Steudel C, Peschel C, Duyster J.
    Blood; 2003 Jul 15; 102(2):646-51. PubMed ID: 12663439
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
    Bagrintseva K, Schwab R, Kohl TM, Schnittger S, Eichenlaub S, Ellwart JW, Hiddemann W, Spiekermann K.
    Blood; 2004 Mar 15; 103(6):2266-75. PubMed ID: 14604974
    [Abstract] [Full Text] [Related]

  • 6. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
    O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM.
    Blood; 2003 May 01; 101(9):3597-605. PubMed ID: 12531805
    [Abstract] [Full Text] [Related]

  • 7. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.
    Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, Jones-Bolin S, Ruggeri B, Dionne C, Small D.
    Blood; 2002 Jun 01; 99(11):3885-91. PubMed ID: 12010785
    [Abstract] [Full Text] [Related]

  • 8. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.
    Yee KW, O'Farrell AM, Smolich BD, Cherrington JM, McMahon G, Wait CL, McGreevey LS, Griffith DJ, Heinrich MC.
    Blood; 2002 Oct 15; 100(8):2941-9. PubMed ID: 12351406
    [Abstract] [Full Text] [Related]

  • 9. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
    Kindler T, Breitenbuecher F, Kasper S, Estey E, Giles F, Feldman E, Ehninger G, Schiller G, Klimek V, Nimer SD, Gratwohl A, Choudhary CR, Mueller-Tidow C, Serve H, Gschaidmeier H, Cohen PS, Huber C, Fischer T.
    Blood; 2005 Jan 01; 105(1):335-40. PubMed ID: 15345593
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
    Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T, Gilliland DG, Griffin JD.
    Cancer Cell; 2002 Jun 01; 1(5):433-43. PubMed ID: 12124173
    [Abstract] [Full Text] [Related]

  • 11. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W.
    Clin Cancer Res; 2003 Jun 01; 9(6):2140-50. PubMed ID: 12796379
    [Abstract] [Full Text] [Related]

  • 12. FLT3-TKD mutation in childhood acute myeloid leukemia.
    Liang DC, Shih LY, Hung IJ, Yang CP, Chen SH, Jaing TH, Liu HC, Wang LY, Chang WH.
    Leukemia; 2003 May 01; 17(5):883-6. PubMed ID: 12750701
    [Abstract] [Full Text] [Related]

  • 13. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).
    Kelly LM, Yu JC, Boulton CL, Apatira M, Li J, Sullivan CM, Williams I, Amaral SM, Curley DP, Duclos N, Neuberg D, Scarborough RM, Pandey A, Hollenbach S, Abe K, Lokker NA, Gilliland DG, Giese NA.
    Cancer Cell; 2002 Jun 01; 1(5):421-32. PubMed ID: 12124172
    [Abstract] [Full Text] [Related]

  • 14. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.
    Reindl C, Bagrintseva K, Vempati S, Schnittger S, Ellwart JW, Wenig K, Hopfner KP, Hiddemann W, Spiekermann K.
    Blood; 2006 May 01; 107(9):3700-7. PubMed ID: 16410449
    [Abstract] [Full Text] [Related]

  • 15. Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype.
    Matsuno N, Osato M, Yamashita N, Yanagida M, Nanri T, Fukushima T, Motoji T, Kusumoto S, Towatari M, Suzuki R, Naoe T, Nishii K, Shigesada K, Ohno R, Mitsuya H, Ito Y, Asou N.
    Leukemia; 2003 Dec 01; 17(12):2492-9. PubMed ID: 14562119
    [Abstract] [Full Text] [Related]

  • 16. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.
    Teller S, Krämer D, Böhmer SA, Tse KF, Small D, Mahboobi S, Wallrapp C, Beckers T, Kratz-Albers K, Schwäble J, Serve H, Böhmer FD.
    Leukemia; 2002 Aug 01; 16(8):1528-34. PubMed ID: 12145694
    [Abstract] [Full Text] [Related]

  • 17. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations.
    Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B, Steffen B, Matsumura I, Kanakura Y, Böhmer FD, Müller-Tidow C, Berdel WE, Serve H.
    Blood; 2003 Apr 15; 101(8):3164-73. PubMed ID: 12468433
    [Abstract] [Full Text] [Related]

  • 18. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.
    Sohal J, Phan VT, Chan PV, Davis EM, Patel B, Kelly LM, Abrams TJ, O'Farrell AM, Gilliland DG, Le Beau MM, Kogan SC.
    Blood; 2003 Apr 15; 101(8):3188-97. PubMed ID: 12515727
    [Abstract] [Full Text] [Related]

  • 19. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
    Müller-Tidow C, Steur C, Mizuki M, Schwäble J, Brandts C, Berdel WE, Serve H.
    Dtsch Med Wochenschr; 2002 Oct 18; 127(42):2195-200. PubMed ID: 12397548
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
    Tse KF, Allebach J, Levis M, Smith BD, Bohmer FD, Small D.
    Leukemia; 2002 Oct 18; 16(10):2027-36. PubMed ID: 12357354
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.